HealthProves
Home/Manufacturers/A-S Medication Solutions
Manufacturer profile

A-S Medication Solutions

Pharmaceutical company56 products tracked
56
products tracked
3,447,028
total reports
425
recalls on record
65.4%
serious overall
Products
showing 56 of 56
ProductApprovedReports ↓Top signalRecalls
1972491,157Systemic lupus erythematosus11
2000308,680Palpitations100
—195,145Chronic kidney disease1
2012171,338Asthma14
1987162,981Synovitis12
1979137,410Hyperkalaemia11
2003130,496Multiple-drug resistance18
1998129,432Psoriatic arthropathy4
1963119,417Drug abuse13
2012118,894Obstructive airways disorder14
2006114,158Obstructive airways disorder2
197499,955End stage renal disease20
201998,103Pulmonary arterial hypertension0
—95,176Obstructive airways disorder1
201486,770Accidental underdose3
201577,542Bone demineralisation3
198666,038Epilepsy12
200064,485Blood glucose decreased5
198263,743Clostridium difficile infection15
199760,586Breast cancer metastatic2
—59,089Obstructive airways disorder0
201456,693Diabetic ketoacidosis1
201541,643Bone demineralisation0
198439,971Alcoholism17
200538,856Blood glucose increased1
—35,132Bone demineralisation0
200134,581Chronic kidney disease11
201330,943Diabetic foot infection1
—26,702Cholestasis5
200226,564Blepharospasm19
200021,326Product delivery mechanism issue9
197121,106Nephrogenic anaemia24
201220,686Tooth injury0
200119,663Wheezing38
200119,655Wheezing0
198018,541Anti-cyclic citrullinated peptide antibody positive13
—17,624Bone density decreased0
197716,938Infusion site pain0
198115,321Suicide attempt0
—10,359Palpitations0
200010,154Product delivery mechanism issue4
19849,868Patient dissatisfaction with treatment1
19769,839Nasal discomfort7
20009,134No adverse event0
19828,566Sopor0
19965,914Chronic kidney disease2
19674,388Vaginal flatulence0
19703,461Rash maculo-papular3
20183,424Blood potassium abnormal0
—3,384Hidradenitis5
19873,377Lymphoedema0
19993,293Asthma0
—2,865Metrorrhagia0
—2,734Device delivery system issue3
20201,984Infusion site irritation0
—1,744Bone demineralisation0
Recall history · 50 on record
DateClassReasonFirm
May 28, 2026IICGMP DeviationsAjanta Pharma USA Inc
Apr 30, 2026IILabeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule.Safecor Health, LLC
Apr 20, 2026IIChemical contamination; presence of lead and lithium above specificationAcella Pharmaceuticals, LLC
Feb 26, 2026IISubpotent DrugMACLEODS PHARMA USA, INC
Dec 31, 2025IIProduct Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.Alvogen, Inc
Dec 18, 2025IIPresence of particulate matter - Glass like particles.Imprimis NJOF, LLC
Oct 13, 2025IISubpotent drug; Clavulanate Potassium componentTeva Pharmaceuticals USA, Inc
Sep 15, 2025IIFailed Dissolution Specifications.Amerisource Health Services LLC
Aug 5, 2025IIPresence of foreign substance: identified as aluminum.SUN PHARMACEUTICAL INDUSTRIES INC
Jul 29, 2025IISubpotent drugPfizer
Jun 20, 2025IISubpotent Drug: Assay below the approved specificationACCORD HEALTHCARE, INC.
Jun 20, 2025IISubpotent Drug: Assay below the approved specificationACCORD HEALTHCARE, INC.
Jun 20, 2025IISubpotent Drug: Assay below the approved specificationACCORD HEALTHCARE, INC.
Jun 20, 2025IISubpotent Drug: Assay below the approved specificationACCORD HEALTHCARE, INC.
Jun 20, 2025IISubpotent Drug: Assay below the approved specificationACCORD HEALTHCARE, INC.
May 28, 2025IILack of Assurance of SterilityApotex Corp.
May 23, 2025IIFailed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.Ascend Laboratories, LLC
May 23, 2025IIFailed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.Ascend Laboratories, LLC
May 13, 2025IIPresence of Foreign Tablets/Capsules: manufacturer recalled because one tadalafil 5mg tablet was found in 500 count bottle of Celecoxib 200 mg capsulesAvKARE
May 9, 2025IIPresence of Foreign Tablets/Capsules; customer complaint found one Tadalafil 5mg tablet inside a sealed 500-count bottle of Celecoxib 200mg capsuleAlembic Pharmaceuticals Limited
Apr 10, 2025IISubpotentACCORD HEALTHCARE, INC.
Apr 10, 2025IISubpotentACCORD HEALTHCARE, INC.
Mar 13, 2025ILABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.Dr. Reddy's Laboratories, Inc.
Mar 13, 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
Mar 13, 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
Mar 7, 2025IISuper-Potent Drug: Out of specification potency results were obtained.Mylan Institutional, Inc.
Feb 25, 2025IIPresence of Foreign Tablets/Capsules.A-S Medication Solutions LLC
Jan 29, 2025IICGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA
Jan 29, 2025IICGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA
Jan 29, 2025IICGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA
Jan 29, 2025IICGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA
Jan 29, 2025IICGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA
Jan 29, 2025IICGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA
Jan 29, 2025IICGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA
Jan 29, 2025IICGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA
Jan 29, 2025IICGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA
Jan 29, 2025IICGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA
Jan 29, 2025IICGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA
Jan 29, 2025IICGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA
Jan 29, 2025IICGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA
Jan 29, 2025IICGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA
Dec 20, 2024IIFailed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term stability study.Lupin Pharmaceuticals Inc.
Nov 19, 2024IISubpotent and Superpotent DrugMylan Institutional, Inc.
Nov 19, 2024IISubpotent and Superpotent DrugMylan Institutional, Inc.
Nov 19, 2024IISubpotent and Superpotent DrugMylan Institutional, Inc.
Nov 19, 2024IISubpotent and Superpotent DrugMylan Institutional, Inc.
Nov 19, 2024IISubpotent and Superpotent DrugMylan Institutional, Inc.
Nov 19, 2024IISubpotent and Superpotent DrugMylan Institutional, Inc.
Nov 18, 2024IISuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc
Nov 18, 2024IISuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc

Class I = reasonable probability of serious harm · Class II = temporary or reversible · Class III = unlikely to cause harm.

Registration status

Some products from A-S Medication Solutions are not FDA-registered for human use. For unregistered substances (peptides, SARMs without human registration), no legitimate human-use supplier exists. The absence of a sourcing route is the safety information.